Affordable Access

deepdyve-link
Publisher Website

Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys.

Authors
  • Al-Abri, Seif Salem1
  • Al-Wahaibi, Adil2
  • Al-Kindi, Hanan3
  • Kurup, Padmamohan J4
  • Al-Maqbali, Ali5
  • Al-Mayahi, Zayid6
  • Al-Tobi, Mohammed Hamed7
  • Al-Katheri, Salim Habbash8
  • Albusaidi, Sultan9
  • Al-Sukaiti, Mahmood Humaid10
  • Al Balushi, Ahmed Yar Mohammed11
  • Abdelgadir, Iyad Omer12
  • Al-Shehi, Nawal13
  • Morkos, Essam14
  • Al-Maani, Amal2
  • Al-Rawahi, Bader2
  • Alyaquobi, Fatma2
  • Alqayoudhi, Abdullah2
  • Al-Harthy, Khalid2
  • Al-Khalili, Sulien2
  • And 27 more
  • 1 Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman. Electronic address: [email protected] , (Oman)
  • 2 Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman. , (Oman)
  • 3 Central Public Health Laboratories, Directorate General for Disease Surveillance and Control, Ministry of Health Muscat, Oman. , (Oman)
  • 4 Department of Disease Surveillance and Control, Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman. , (Oman)
  • 5 Department of Disease Surveillance and Control, Directorate General of Health Services, North Batinah Governorate, Ministry of Health, Sohar, Oman. , (Oman)
  • 6 Department of Disease Surveillance and Control, Directorate General of Health Services, South Batinah Governorate, Ministry of Health, Rustaq, Oman. , (Oman)
  • 7 Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhakhiliya Governorate, Ministry of Health, Nizwa, Oman. , (Oman)
  • 8 Department of Disease Surveillance and Control, Directorate General of Health Services, Dhofar Governorate, Ministry of Health, Salalah, Oman. , (Oman)
  • 9 Department of Disease Surveillance and Control, Directorate General of Health Services, North Sharqiah Governorate, Ministry of Health, Ibra, Oman. , (Oman)
  • 10 Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Dhahira Governorate, Ministry of Health, Ibri, Oman. , (Oman)
  • 11 Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Buraimi Governorate, Ministry of Health, Buraimi, Oman. , (Oman)
  • 12 Department of Disease Surveillance and Control, Directorate General of Health Services, South Sharqiah Governorate, Ministry of Health, Sur, Oman. , (Oman)
  • 13 Department of Disease Surveillance and Control, Directorate General of Health Services, Musandam Governorate, Ministry of Health, Khasab, Oman. , (Oman)
  • 14 Department of Disease Surveillance and Control, Directorate General of Health Services, Al-Wusta Governorate, Ministry of Health, Haima, Oman. , (Oman)
  • 15 Directorate General of Health Services, Muscat Governorate, Ministry of Health, Muscat, Oman. , (Oman)
  • 16 Health Services, Petroleum Development Oman, Muscat, Oman. , (Oman)
  • 17 Directorate General of Primary Health Care, Ministry of Health, Muscat, Oman. , (Oman)
Type
Published Article
Journal
International Journal of Infectious Diseases
Publisher
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Publication Date
Sep 30, 2021
Volume
112
Pages
269–277
Identifiers
DOI: 10.1016/j.ijid.2021.09.062
PMID: 34601146
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To assess the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Oman and longitudinal changes in antibody levels over time within the first 11 months of the coronavirus disease 2019 (COVID-19) pandemic. This nationwide cross-sectional study was conducted as a four-cycle serosurvey using a multi-stage stratified sampling method from July to November 2020. A questionnaire was used and included demographics, history of acute respiratory infection and list of symptoms, COVID-19 contact, previous diagnosis or admission, travel history and risk factors. In total, 17,457 participants were surveyed. Thirty percent were female and 66.3% were Omani. There was a significant increase in seroprevalence throughout the study cycles, from 5.5% (4.8-6.2%) in Cycle 1 to 22% (19.6-24.6%) in Cycle 4. There was no difference in seroprevalence between genders, but significant differences were found between age groups. There was a transition of seroprevalence from being higher in non-Omanis than Omanis in Cycle 1 [9.1% (7.6-10.9%) vs 3.2% (2.6-3.9%)] to being higher in Omanis than non-Omanis in Cycle 4 [24.3% (21.0-27.9%) vs 16.8% (14.9-18.9%)]. There was remarkable variation in the seroprevalence of SARS-CoV-2 according to governorate. Close contacts of people with COVID-19 had a 96% higher risk of having the disease [adjusted odds ratio (AOR) 1.96, 95% confidence intervals (CI) 1.64-2.34]. Labourers had 58% higher risk of infection compared with office workers (AOR 1.58, 95% CI 1.04-2.35). This study showed a wide variation in the spread of SARS-CoV-2 across governorates in Oman, with higher estimated seroprevalence in migrants in the first two cycles. Prevalence estimates remain low and are insufficient to provide herd immunity. Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Report this publication

Statistics

Seen <100 times